Remove Artificial Inteligence Remove Artificial Intelligence Remove Business Transformation Remove Pharmaceuticals
article thumbnail

Cardinal Health CIO Michelle Greene on simplifying transformation

CIO

Recently, I had the pleasure of speaking with Michelle Greene, who was promoted from SVP of EIT of Cardinal Health’s pharmaceutical segment to CIO last August. Just three months into her tenure, Greene is already having an impact reorganizing IT — from application support to data analytics — for business impact.

Analytics 299
article thumbnail

Cardinal Health CIO Michelle Greene on simplifying transformation

CIO

Recently, I had the pleasure of speaking with Michelle Greene, who was promoted from SVP of EIT of Cardinal Health’s pharmaceutical segment to CIO last August. Just three months into her tenure, Greene is already having an impact reorganizing IT — from application support to data analytics — for business impact.

Analytics 246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

IoT, AI, Blockchain: what does the future hold for mobile Healthcare

Apiumhub

Thanks to Artificial Intelligence, Blockchain, and IoT, people have to make fewer visits to the doctor and can stay inter-connected through a computer or mobile phones only. 2- Artificial Intelligence. Another wave of the future in healthcare is artificial intelligence. Top business blogs to read.

article thumbnail

And the winners are…. Congratulations to the Sixth Annual Data Impact Awards winners

Cloudera

The week is typically filled with exciting announcements from Cloudera and many partners and others in the data management, machine learning and analytics industry. Enterprise Machine Learning: . It’s a big week for us, as many Clouderans descend on New York for the Strata Data Conference. Technical Impact.

article thumbnail

Can data drive more successful R&D in life sciences?

Capgemini

Newly qualified data scientists who haven’t worked in R&D-heavy organizations, including life sciences and healthcare, can struggle to understand the pharmaceutical science and drug approval process, how best to represent and interpret it accurately with their tools, or where to focus their efforts. Experience and insight for the future.

Data 98